JP2022525705A - ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法 - Google Patents
ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法 Download PDFInfo
- Publication number
- JP2022525705A JP2022525705A JP2022504490A JP2022504490A JP2022525705A JP 2022525705 A JP2022525705 A JP 2022525705A JP 2022504490 A JP2022504490 A JP 2022504490A JP 2022504490 A JP2022504490 A JP 2022504490A JP 2022525705 A JP2022525705 A JP 2022525705A
- Authority
- JP
- Japan
- Prior art keywords
- fine particles
- drug
- steroid
- biodegradable polymer
- prednisolone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
- B01J37/32—Freeze drying, i.e. lyophilisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (15)
- (a)ステロイド系薬物及び生分解性ポリエステル系高分子混合物を有機溶媒に溶解させ、ステロイド系薬物及び生分解性ポリエステル系高分子を含む溶液を製造する段階;
(b)前記ステロイド系薬物及び生分解性ポリエステル系高分子を含む溶液を、有機溶媒の融点未満温度のC5~10の炭化水素溶液に噴射させて微細粒子を製造する段階;
(c)前記微細粒子を塩水溶液に添加して有機溶媒を溶解させて有機溶媒を除去する段階;及び、
(d)前記有機溶媒が除去された微細粒子から塩を除去する段階;からなる
ことを特徴とするステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記(a)段階の溶解は、ステロイド系薬物及び生分解性ポリエステル系高分子混合物が溶液を基準に1~25%(w/v)となるように有機溶媒に溶かす
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記(a)段階のステロイド系薬物及び生分解性ポリエステル系高分子混合物は、ステロイド系薬物及び生分解性ポリエステル系高分子が1:99~3:7重量比で混合されている
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記生分解性ポリエステル系高分子は、重量平均分子量が10,000~250,000である
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記有機溶媒は、DMSO(dimethyl sulfoxide)、PCL(poly caprolactone)、クロロホルム(chloroform)、アセトン(acetone)、ジクロロメタン(dichloromethane)、ベンゼン(benzene)、トルエン(toluene)、イソプロピルエーテル(isopropyl ether)、クロロベンゼン(chlorobenzene)からなる群から選ばれる1種以上である
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記(b)段階のC5~10の炭化水素(hydrocarbon)は、ペンタン(pentane)、ヘキサン(hexane)、ヘプタン(hepatane)、オクタン(octane)、ノナン(nonane)、デカン(decane)及び石油エーテル(petroleum ether)からなる群から選ばれる1種以上である
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記(c)段階の塩水溶液は、5~30%(w/v)のNaCl又はCaCl2水溶液である
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記ステロイド系薬物を含む生分解性高分子微細粒子は、直径が10~1000μmである
請求項1に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記ステロイド系薬物は、デフラザコート(deflazacort)、デソニド(desonide)、デソキシメタゾン(desoximetasone)、デキサメタゾン(dexamethasone)、ジフロラゾン(diflorasone)、ジフルコルトロン(diflucortolone)、ジフルプレドナート(difluprednate)、エタボン酸ロテプレドノール(loteprednol etabonate)、リメキソロン(rimexolone)、マジプレドン(mazipredone)、メドリゾン(medrysone)、メチルプレドニゾロン(methylprednisolone)、メプレドニゾン(meprednisone)、モメタゾンフロエート(mometasone furoate)、ベクロメタソン(beclomethasone)、ベタメサゾン(betamethasone)、ブデソニド(budesonide)、アルゲストン(algestone)、アルクロメタゾン(alclometasone)、アムシノニド(amcinonide)、エノキソロン(enoxolone)、コルチコステロン(corticosterone)、コーチゾン(cortisone)、コルチバゾール(cortivazol)、クロロプレドニゾン(chloroprednisone)、クロベタゾール(clobetasol)、クロベタゾン(clobetasone)、クロコルトロン(clocortolone)、クロプレドノール(cloprednol)、チキソコルトール(tixocortol)、トリアムシノロン(triamcinolone)、トリアムシノロンアセトニド(triamcinolone acetonide)、トリアムシノロンベネトニド(triamcinolone benetonide)、トリアムシノロンヘキサセトニド(triamcinolone hexacetonide)、パラメタゾン(paramethasone)、プレグネノロンアセテート(pregnenolone acetate)、プレドニカルベート(prednicarbate)、プレドニゾロン(prednisolone)、プレドニゾロン25-ジエチルアミノアセテート(prednisolone 25-diethylaminoacetate)、プレドニゾロンリン酸エステルナトリウム(prednisolone sodium phosphate)、プレドニゾン(prednisone)、プレドニバール(prednival)、プレドニリデン(prednylidene)、フルアザコート(fluazacort)、フルクロロニド(flucloronide)、フルメタゾン(flumethasone)、フルニソリド(flunisolide)、フルオシノロンアセトニド(fluocinolone acetonide)、フルオシノニド(fluocinonide)、フルオコルチンブチル(fluocortin butyl)、フルオコルトロン(fluocortolone)、フルオロメトロン(fluorometholone)、フルペロロンアセテート(fluperolone acetate)、フルプレドニデンアセテート(fluprednidene acetate)、フルプレドニソロン(fluprednisolone)、フルドロキシコルチド(flurandrenolide)、フルチカゾンプロピオネート(fluticasone propionate)、ホルモコータル(formocortal)、ハルシノニド(halcinonide)、ハロベタゾールプロピオネート(halobetasol propionate)、ハロメタゾン(halometasone)、ハロプレドンアセテート(halopredone acetate)、ヒドロコルタメート(hydrocortamate)、ヒドロコルチゾン(hydrocortisone)及び性ホルモン(sex hormone)からなる群から選ばれる1種以上である
請求項1ないし8のいずれかに記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記性ホルモンは、プロゲステロン(Progesterone)、テストステロン(Testosterone)、エストロゲン(Estrogen)、アンドロゲン(Androgen)、エストラジオール(Estradiol)、レボノルゲストレル(Levonorgestrel)、ゲストデン(Gestodene)、デソゲストレル(Desogestrel)、ジエノゲスト(Dienogest)、シプロテロンアセテート(Cyproterone acetate)及びエチニルエストラジオール(Ethynylestradiol)からなる群から選ばれる1種以上である
請求項9に記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 前記生分解性ポリエステル系高分子は、ポリ乳酸(poly lactic acid,PLA)、ポリグリコール酸(poly glycolic acid,PGA)、ポリ-D,L-ラクチド(poly-D,L-lactide,PDLLA)、ポリ(D,L-ラクティク-co-グリコール酸)(poly(D,L-lactic-co-glycolic acid)、PLGA)、ポリカプロラクトン(poly-carprolactone,PCL)、ポリ(バレロラクトン)(poly(valerolactone))、ポリ(ヒドロキシブチレート)(poly(hydroxy butylate))及びポリ(ヒドロキシバレラート)(poly(hydroxy valerate))からなる群から選ばれる1種以上である
請求項1ないし8のいずれかに記載のステロイド系薬物を含む生分解性高分子微細粒子の製造方法。 - 請求項1ないし8のいずれかに記載の製造方法で製造された
ことを特徴とするステロイド系薬物を含む生分解性高分子微細粒子。 - 請求項12のステロイド系薬物を含む
ことを特徴とする生分解性高分子微細粒子を含有する抗炎症組成物。 - 請求項12のステロイド系薬物を含む
ことを特徴とする生分解性高分子微細粒子を含有する性ホルモン製剤。 - 前記性ホルモン製剤は、注射剤である
請求項14に記載の性ホルモン製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0031072 | 2019-03-19 | ||
KR1020190031072A KR102377975B1 (ko) | 2019-03-19 | 2019-03-19 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
KR1020190179090A KR102404224B1 (ko) | 2019-12-31 | 2019-12-31 | 성호르몬계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
KR10-2019-0179090 | 2019-12-31 | ||
PCT/KR2020/000413 WO2020189886A2 (ko) | 2019-03-19 | 2020-01-09 | 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022525705A true JP2022525705A (ja) | 2022-05-18 |
JP7296520B2 JP7296520B2 (ja) | 2023-06-22 |
Family
ID=72520356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022504490A Active JP7296520B2 (ja) | 2019-03-19 | 2020-01-09 | ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11376226B2 (ja) |
EP (1) | EP3943073A4 (ja) |
JP (1) | JP7296520B2 (ja) |
CN (1) | CN112955129A (ja) |
WO (1) | WO2020189886A2 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525403A (ja) * | 2002-05-03 | 2005-08-25 | ピーアール ファーマシューティカルズ, インコーポレイテッド | エストラジオール代謝産物の徐放性組成物 |
US20110245456A1 (en) * | 2009-06-05 | 2011-10-06 | Regen Biotech Inc. | Biodegradable polymer microparticles and preparation method thereof |
JP2013535489A (ja) * | 2010-08-04 | 2013-09-12 | フレクシオン セラピューティックス インコーポレイテッド | 関節痛の治療のためのコルチコステロイド |
US20160002393A1 (en) * | 2013-02-22 | 2016-01-07 | Vaim Co., Ltd. | Method for preparing polymer microparticles by spray process |
KR20180018892A (ko) * | 2016-08-09 | 2018-02-22 | 단국대학교 천안캠퍼스 산학협력단 | 안정한 결정형 약물을 포함하는 고분자 미립구 및 그 제조방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
EP0765660A3 (en) * | 1995-09-28 | 1998-09-23 | Takeda Chemical Industries, Ltd. | Microcapsules comprising 2-piperazinone-1-acetic acid compounds |
US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
KR20070107941A (ko) | 2006-05-04 | 2007-11-08 | 동아제약주식회사 | 개선된 방출 양상을 갖는 인간성장호르몬 지속제어 방출생분해성 고분자의 약학적 조성물 및 미립구 제형 |
KR100963435B1 (ko) | 2008-06-19 | 2010-06-17 | 한국과학기술연구원 | 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법 |
CA2743600C (en) * | 2008-11-14 | 2016-11-08 | Ewha University-Industry Collaboration Foundation | Method for preparing microspheres and microspheres produced thereby |
KR101481859B1 (ko) | 2011-05-20 | 2015-01-14 | 에스케이케미칼주식회사 | 초기 약물 방출이 감소된 고분자 미립자의 제조방법 및 그 방법에 의해 제조된 고분자 미립자 |
KR101943473B1 (ko) | 2015-06-26 | 2019-01-29 | 주식회사 엘지화학 | 폴리머 입자의 제조방법 |
-
2020
- 2020-01-09 WO PCT/KR2020/000413 patent/WO2020189886A2/ko unknown
- 2020-01-09 JP JP2022504490A patent/JP7296520B2/ja active Active
- 2020-01-09 US US16/756,306 patent/US11376226B2/en active Active
- 2020-01-09 EP EP20774762.7A patent/EP3943073A4/en active Pending
- 2020-01-09 CN CN202080000471.6A patent/CN112955129A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005525403A (ja) * | 2002-05-03 | 2005-08-25 | ピーアール ファーマシューティカルズ, インコーポレイテッド | エストラジオール代謝産物の徐放性組成物 |
US20110245456A1 (en) * | 2009-06-05 | 2011-10-06 | Regen Biotech Inc. | Biodegradable polymer microparticles and preparation method thereof |
JP2013535489A (ja) * | 2010-08-04 | 2013-09-12 | フレクシオン セラピューティックス インコーポレイテッド | 関節痛の治療のためのコルチコステロイド |
US20160002393A1 (en) * | 2013-02-22 | 2016-01-07 | Vaim Co., Ltd. | Method for preparing polymer microparticles by spray process |
KR20180018892A (ko) * | 2016-08-09 | 2018-02-22 | 단국대학교 천안캠퍼스 산학협력단 | 안정한 결정형 약물을 포함하는 고분자 미립구 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
JP7296520B2 (ja) | 2023-06-22 |
WO2020189886A9 (ko) | 2021-07-15 |
CN112955129A (zh) | 2021-06-11 |
US20210212956A1 (en) | 2021-07-15 |
US11376226B2 (en) | 2022-07-05 |
WO2020189886A2 (ko) | 2020-09-24 |
EP3943073A4 (en) | 2023-01-04 |
EP3943073A2 (en) | 2022-01-26 |
WO2020189886A3 (ko) | 2021-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100483447B1 (ko) | 고체 또는 반-고체의 국부 투입 장치와 비경구적 투약을 위한 서방성 제제와 그 제제의 제조 방법 | |
KR100913910B1 (ko) | 호르몬 보충 요법용 드로스피렌온 | |
TWI576107B (zh) | 釋放芳香化酶抑制劑及促孕素以治療子宮內膜異位症之非口服劑型 | |
US5137669A (en) | Manufacture of partially fused peptide pellet | |
CN101816662B (zh) | 由雌二醇和胆固醇组成的稳定形状颗粒的制备方法 | |
US10406099B2 (en) | Bioerodible contraceptive implant and methods of use thereof | |
US20090270308A1 (en) | Controlled release implantable dispensing device and method | |
EP1100509B1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
JP2010077149A (ja) | エストロゲン補充療法を受けている女性のホルモン不足の治療方法 | |
Cutler et al. | Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury | |
DE60223795T2 (de) | Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption | |
CN108703942A (zh) | 载有纳米材料包裹保胎药物的微针给药系统及制备方法 | |
Patil et al. | Advances in progesterone delivery systems: Still work in progress? | |
DE202011110355U1 (de) | Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes | |
JP7296520B2 (ja) | ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法 | |
CA2759807C (en) | Controlled release dispensing device | |
RU2786452C1 (ru) | Микрочастица биоразлагаемого полимера, содержащая лекарственное средство на основе стероида, и способ ее получения | |
KR102404224B1 (ko) | 성호르몬계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법 | |
US20100173000A1 (en) | Controlled release implantable dispensing device and method | |
Timble et al. | RECENT ADVANCEMENTS IN PROGESTERONE DELIVERY SYSTEMS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210917 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230606 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230612 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7296520 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |